Clinical trials: Sadness
Healthy Volunteers
QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects
The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling a total of five ~ six cohorts of healthy participants, a multiple-dose ascending (MAD) phase (Part B) enrolling 3 cohorts of healthy…
- Trial name
- NCT05650528
- Testing
- QG101-23-0 capsules
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Amckaus PTY LTD.
Healthy Subjects
A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.
- Trial name
- NCT05503693
- Testing
- AP303 50 μg, AP303 150 μg, AP303 300 μg
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Alebund Pty Ltd
Small Airway Disease, Asthma
Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab (SASAM Study)
Rationale Although the majority of asthma patients can be effectively treated with currently available medications, a substantial subset remains severe, causing a considerable proportion of resource expenditure.
- Trial name
- SASAM (NCT05040997)
- Testing
- Small airways assessment
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Seasonal Affective Disorder
Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
The purpose of this study is to determine whether treating sleep difficulties in patients with seasonal affective disorder also improves their depressive symptoms.
- Trial name
- SAM-SAD (NCT00502320)
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Lehigh Valley Hospital
Phobia, Social
Gaze Contingent Feedback in Social Anxiety Disorder
The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)
- Trial name
- NCT02590770
- Testing
- attention modification
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Tel Aviv University
Mood Disorder
The Role of Emotion in the Development of Psychopathology
The dysregulated experience and expression of emotion is implicated in psychiatric disorders associated both with externalizing problems (aggressive, antisocial behaviors) and internalizing problems (anxiety, depression).
- Trial name
- NCT00001654
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Healthy Volunteers
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
- Trial name
- NCT07248865
- Testing
- CLYM116
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Climb Bio, Inc.
Tuberculosis
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study.
- Trial name
- NCT05824091
- Testing
- MK-7762 (TBD09)
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD)
Stepped Care Treatment for Anxiety Resilience
Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD.
- Conditions
- Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Separation Anxiety Disorder, Specific Phobia
- Trial name
- STAR (NCT07228143)
- Testing
- Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A)
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Andrew Wiese
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Diabetes Mellitus
To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multi-dose, sequential, bridging study in healthy volunteer using YG1699 .
- Trial name
- NCT05089617
- Testing
- YG1699
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Youngene Therapeutics Inc., Ltd.
Social Anxiety Disorder
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women.
- Trial name
- NCT02622958
- Testing
- PH94B
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Social Phobia
A Combination Therapy In Patients With Social Anxiety Disorder
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)
- Trial name
- NCT00403962
- Testing
- vestipitant/paroxetine
- Where
- 17 sites in Denmark, Germany and 2 more
- Volunteers
- 204 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
First-in-Human Single and Multiple Dose of EB8018
The purpose of this study is to determine the safety profile of single and multiple doses of EB8018 in healthy male subjects, to determine the pharmacokinetic profile of single and multiple doses of EB8018 in healthy male…
- Trial name
- NCT02998190
- Testing
- Single Ascending Doses of EB8018, Multiple Ascending Doses of EB8018
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Enterome
Cystic Fibrosis
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P.
- Trial name
- NCT03669614
- Testing
- Inhaled AR-501
- Where
- 25 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aridis Pharmaceuticals, Inc.
Healthy Volunteers
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants.
- Trial name
- NCT07429006
- Testing
- AKB-9090
- Where
- New Zealand
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Healthy
A First-in-Human Safety Trial of MTX-463
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in…
- Trial name
- NCT06401213
- Testing
- MTX-463
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Social Anxiety Disorder
Geodon for the Treatment of Refractory Social Anxiety Disorder
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment…
- Trial name
- SAD (NCT00215150)
- Testing
- Ziprasidone, Sertraline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Parkinson Disease
First-in-Human Single and Multiple Dose of HL-400
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending…
- Trial name
- NCT06997484
- Testing
- HL-400
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Highlightll Pharmaceutical (USA) LLC
Major Depressive Disorder
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042562
- Testing
- duloxetine
- Where
- 23 sites in United States
- Sponsor
- Eli Lilly and Company